UPCC 09220: Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Esophagogastric Adenocarcinoma
Enrolling By Invitation
99 years or below
All
Phase
2
1 Location
Brief description of study
The purpose of this study is to test the effects of the research study drug Telomelysin (OBP-301) in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. Eligible subjects are those with advanced or metastatic cancer of the stomach or junction between the stomach and esophagus.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: gastroesophageal junction cancer, stomach cancer
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 843696
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
